… established atherosclerotic cardiovascular disease (HR, 0.86; 95… (HR, 1.01; 95% CI, 0.87–1.19;
P=0.81; P interaction, 0.028). SGLT2i reduced hospitalization for heart failure by 31% (HR…

… , 0.76 [95% CI, 0.62–0.92]), it reduced cardiovascular death only in patients with HFrEF (HR, …
Dr Wilding reports personal fees and other from Brigham and Women’s Hospital; grants, …

Ormaplatin (NSC 363812, tetraplatin) is a stable platinum (IV) analog which has exhibited
activity against cisplatin-resistant cell lines. A phase I trial of ormaplatin administered as a 1-h …

… protocol but without the one-hour period of circulatory arrest. … We conclude that one hour
of circulatory arrest under … survival in dogs that underwent one hour of circulatory arrest at 0…

The increasing number of accidents associated with off-road motor vehicles used for
recreational purposes prompted this prospective study. During 1985 the records of victims of all …

… For the analysis of natural history evaluating the risk of outcomes comparing patients with
and without PAD, a multivariable-adjusted HR was obtained from a Cox model that included …

… Similarly, presence of atherosclerotic cardiovascular disease (HR, 0.83 [95% CI, 0.66–1.04])
versus multiple risk factors (HR, 0.78 [95% CI, 0.62–0.99]; P for interaction 0.72) or a history …

… to reduce the risk of death (HR: 0.68) and hospitalization for HF (HR: 0.65). All patients …
significant reduction seen in the subgroup without established CVD (HR: 0.98; 95% CI: 0.74 to …

Background -Reduction in cardiovascular death and hospitalization for heart failure (HHF)
was recently reported with the sodium-glucose co-transporter-2 inhibitor (SGLT-2i) …

… Each volunteer drank approximately 100 ml of water every hour postdose for the first 4 hr.
A standard lunch and dinner were provided at 4 and 9 hr postdose, respectively. Fluid was …